Infectious Disease Epidemiology and Pharmaceutical Development in the Era of Antimicrobial Resistance (AMR)
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 53
Special Issue Editor
2. County Clinical Emergency Hospital, Sibiu, Romania
Interests: COVID-19; sepsis; clostridioides difficile; respiratory tract infections; bacterial infections; viral infections; arboviral disease; hospital aquired infections; bone and joint infection; surgical site infections
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antimicrobial resistance (AMR) is widely recognized as one of the most significant global health threats of the 21st century. Current estimates suggest that, by 2050, drug-resistant infections may result in up to 10 million deaths annually. The increasing prevalence of multidrug-resistant organisms, coupled with the inappropriate or excessive use of antimicrobials, has led to an urgent need for comprehensive strategies that address surveillance, early diagnosis, therapeutic innovation, and antimicrobial stewardship.
Local and global epidemiological data are essential in guiding empirical treatment decisions, particularly in critically ill patients and those with high-risk infections. Recognizing the true scale of resistance supports critical decisions regarding the rational use of antibiotics and the cyclic withdrawal of entire antibiotic classes rendered ineffective due to high resistance rates. In parallel, the advancement of rapid diagnostic methods, the development of novel antimicrobial agents, and the implementation of stewardship programs are central pillars in combating AMR.
In this context, I am pleased to announce the launch of a Special Issue entitled “Infectious Disease Epidemiology and Pharmaceutical Development in the Era of Antimicrobial Resistance (AMR)”.
This Special Issue aims to highlight interdisciplinary approaches to the study and management of AMR, bringing together insights from microbiology, infectious diseases, epidemiology, clinical pharmacology, and public health. We invite the submission of original research articles, systematic reviews, and perspective pieces focusing on topics including, but not limited to:
- Drug discovery and pharmaceutical development targeting resistant organisms;
- Antimicrobial resistance surveillance (local, national, or global levels);
- Mechanisms of resistance in clinically significant pathogens;
- Rapid diagnostic techniques and point-of-care testing;
- Antimicrobial stewardship strategies across healthcare settings;
- Epidemiological studies of healthcare-associated and community-acquired infections;
- Clinical outcomes and case reports involving multidrug-resistant infections.
Through this Special Issue, we aim to foster the exchange of knowledge and experience that will support the development of effective strategies to mitigate AMR and improve patient care.
We look forward to receiving your valuable contributions.
Sincerely,
Prof. Dr. Victoria Birlutiu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antimicrobial resistance (AMR)
- antibiotic stewardship
- multidrug-resistant organisms (MDROs)
- infectious disease epidemiology
- rapid diagnostics
- antimicrobial surveillance
- therapeutic development
- resistance mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
